Los Angeles Capital Management LLC Sells 1,163 Shares of Hologic, Inc. (NASDAQ:HOLX)

Los Angeles Capital Management LLC reduced its position in Hologic, Inc. (NASDAQ:HOLX) by 21.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,240 shares of the medical equipment provider’s stock after selling 1,163 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Hologic were worth $345,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Innealta Capital LLC purchased a new stake in Hologic in the 2nd quarter worth about $25,000. Wolff Wiese Magana LLC purchased a new stake in Hologic in the 3rd quarter worth about $25,000. iA Global Asset Management Inc. purchased a new stake in Hologic in the 1st quarter worth about $37,000. Sunbelt Securities Inc. purchased a new stake in Hologic in the 2nd quarter worth about $37,000. Finally, Cromwell Holdings LLC raised its position in Hologic by 330.2% in the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 416 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on HOLX. Stephens reaffirmed an “overweight” rating and set a $92.00 target price on shares of Hologic in a research report on Tuesday, July 30th. Mizuho reduced their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Citigroup lowered shares of Hologic from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $95.00 to $85.00 in a research report on Tuesday, October 1st. JPMorgan Chase & Co. raised their target price on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Finally, Leerink Partners reduced their target price on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $89.91.

Hologic Stock Performance

Shares of HOLX stock opened at $78.60 on Monday. The firm has a market cap of $18.26 billion, a price-to-earnings ratio of 23.60, a PEG ratio of 2.48 and a beta of 0.98. Hologic, Inc. has a 52-week low of $67.59 and a 52-week high of $84.67. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The company’s 50 day moving average is $80.71 and its 200 day moving average is $78.26.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. The company had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. Hologic’s revenue was up 4.5% compared to the same quarter last year. During the same period last year, the firm earned $0.89 earnings per share. On average, sell-side analysts anticipate that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.